EYECARE CooperVision’s MiSight 1 Day Myopia Control Contact Lens Is Honored by German Design Council By Staff Monday, October 3, 2022 12:18 AM (L to R) CooperVision DACH Team Marc von der Burg, Johannes Zupfer, Jerome Kuzio and Ana Stock. SAN RAMON, Calif.—CooperVision’s MiSight 1 day myopia control contact lens was recently recognized in the German Design Council’s 2022 German Innovation Awards. In the field of Medical & Health, it received a special mention in Excellence in Business to Consumer. “This award represents a tremendous sense of achievement and means a lot to us,” said Johannes Zupfer, general manager of Germany, Austria and Switzerland at CooperVision. “On the one hand, it reflects our competence in terms of developing innovative contact lenses. But it also underscores our commitment to delivering solutions to our retail partners that will provide them with the best possible support in their day-to-day business.” Zupfer continued, “Building a successful myopia management program is extremely important and the right thing to do, given the growing number of children with myopia. Providing myopia control contact lenses early on, which both correct refractive error in age-appropriate children and can help to reduce the rate of myopia progression, lowers the risk of eye disease and can contribute to a child’s quality of life. That is and always has been our motivating force.” The German Innovation Award is given for products, technologies and services that break new ground in terms of innovation and for solutions that clearly stand out from conventional approaches. The distinction "Special Mention" is awarded to innovations distinguished for their well-conceived individual features, innovative approaches or skillfully detailed solutions. A daily disposable, dual-focus contact lens designed to slow myopia progression in children, MiSight 1 day is available in more than 30 countries. It has received CE certification, as well as approval from the U.S. FDA and Chinese NMPA. A seven-year, international study of the lens has shown sustained slowing of eye growth over time and that the mean axial elongation showed no evidence of rebound.